Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 7Phase 1/2 5Phase 1 5Phase NA 2Phase 4 1Phase 2/3 1

Status

Recruiting 23Withdrawn 7Completed 7Unknown 5Terminated 4Active not recruiting 4Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 4HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Carcinoma, Ductal, Breast 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Fulvestrant × Clear all
NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Fudan University

Phase 1/2 Unknown
72 enrolled
Breast

Breast Neoplasms

NCT05792410 2023-03-31

A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Fudan University

Phase 1/2 Unknown
59 enrolled
Breast

Breast Neoplasms

NCT02983071 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

G1 Therapeutics, Inc.

Phase 1/2 Unknown
102 enrolled
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT04355520 2020-04-21

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
42 enrolled
Breast

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡